Source link : https://www.newshealth.biz/health-news/everolimus-offers-no-survival-benefit-in-non-clear-cell-rcc/
TOPLINE: Adjuvant everolimus does not improve recurrence-free or overall survival in patients with papillary and chromophobe subtypes of non–clear cell renal cell carcinoma ( RCC) and is associated with higher rates of severe adverse events compared with placebo. METHODOLOGY: Non–clear cell RCC accounts for approximately 25% of RCC cases and includes various distinct tumor types […]
Author : News Health
Publish date : 2024-08-30 12:54:21
Copyright for syndicated content belongs to the linked Source.